Yseop in 2023: A Year of Growth, Gratitude, & GenAI

Share This Post

As we bid farewell to 2023 and reflect on a year filled with groundbreaking developments in generative AI, let’s look back on the significant milestones and events that defined Yseop’s journey in life sciences this year.

Year in review
Yseop kicked off the year by unveiling a new website. With the refresh came an improved user and navigation experience. We also made it easier to maneuver our content repository, with a new podcast and resources section. 

In mid-2023, Yseop marked a pivotal milestone with the introduction of Yseop Copilot, an advanced content automation solution designed for the BioPharma industry. Utilizing pre-trained Generative AI (GenAI) models, Yseop Copilot is the most secure digital colleague for scientific writers. The platform brings a substantial boost to writing and reviewing productivity, guaranteeing quality control, and dramatically reducing writing times across hundreds of clinical trials. 

Emmanuel Walckenaer, CEO of Yseop, took the spotlight in Fierce Electronics in April, sharing how GenAI is reshaping the drug discovery process. He emphasized the necessity for closed-source solutions in regulated industries and advocated for the effectiveness of a hybrid model. 

Recognition from industry leaders

    These recognitions highlight Yseop’s pioneering applications in AI, machine learning, and Natural Language Generation (NLG), and showcase our unfailing commitment to excellence. 


    Collaborating with top 20 pharma companies 

    In August we announced our collaboration with GSK, a leading biopharmaceutical company. We helped transform and streamline their clinical document automation for unparalleled efficiency and productivity. By working together, GSK continues to apply technology to improve clinical timelines and enhance efficiencies in Development. This is one of several initiatives that GSK is taking to accelerate regulatory submissions and get medicines and vaccines to patients faster. 

    2023 ends on an exciting note with a strategic investment from Novartis. They join existing investors Eli Lilly, NextStage AM, and Wille Finance. With the most recent investment, Yseop will continue to execute on its roadmap to automate the entire document process across pharma, from preclinical trials all the way through FDA approval.

    Holiday Wishes

    2023 has indeed been a remarkable year for Yseop, marked by a relentless pursuit of excellence and a commitment to human-centric AI, innovation, and ethics. As we approach the festive season, Yseop extends warm holiday wishes to our community: our clients, partners and employees. May this time bring you joy and peace as we look ahead to a future filled with possibilities! 

    To learn more about Yseop Copilot, start your free automated content generation trial here. For more information on how we can help your organization, please contact

    Scroll to Top